RGS2 Gene Polymorphisms Predict Antipsychotic EPS Susceptibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively assess an individual's susceptibility to extrapyramidal symptoms (EPS) before initiating antipsychotic treatment, leading to suboptimal treatment regimens and potential worsening of symptoms.
Innovation Solution
The use of specific single nucleotide polymorphisms (SNPs) and haplotypes in the RGS2 gene to predict resistance or susceptibility to EPS, allowing for personalized treatment planning by determining the genetic propensity for developing or worsening EPS during antipsychotic drug treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If typical antipsychotic drugs are used to treat psychosis, then antipsychotic efficacy is improved, but extrapyramidal symptoms worsen
Solution Approach 1:
The patent performs genetic testing for RGS2 polymorphisms before initiating antipsychotic treatment to predict EPS susceptibility. This preliminary action allows clinicians to select appropriate treatments in advance, preventing EPS development before it occurs. Patients with high-risk genotypes can be prescribed alternative medications or preventive strategies before exposure to antipsychotic drugs.
Solution Approach 2:
The patent identifies specific genetic variations (polymorphisms) in the RGS2 gene that confer differential susceptibility to EPS. By detecting these local genetic characteristics, the invention enables personalized treatment selection tailored to each patient's genetic profile, allowing high-risk patients to receive different medications than low-risk patients.
2Object-affected harmful factors
If atypical antipsychotic drugs are used to reduce EPS, then extrapyramidal symptoms are improved, but clinical efficacy worsens
Solution Approach 1:
The patent enables differentiation of patients based on their RGS2 genetic profile, allowing clinicians to prescribe atypical antipsychotics specifically to high-risk patients who would benefit from reduced EPS, while prescribing typical antipsychotics to low-risk patients who can tolerate higher efficacy medications. This localized treatment approach optimizes both efficacy and side effect profiles for different patient subgroups.
Solution Approach 2:
By conducting genetic assessment before treatment initiation, the patent allows clinicians to pre-select the most appropriate antipsychotic class for each patient. High-risk patients can be started on atypical antipsychotics from the beginning to prevent EPS, while low-risk patients can receive typical antipsychotics for maximum efficacy, avoiding the need to switch medications later.
3Reliability
If combination therapy with typical and atypical antipsychotics is used to improve clinical efficacy, then antipsychotic efficacy is improved, but extrapyramidal symptoms worsen
Solution Approach 1:
The patent performs genetic testing before initiating combination therapy to identify patients at high risk for EPS. This preliminary risk assessment allows clinicians to avoid combination therapy in high-risk patients or to implement preventive measures, while allowing combination therapy in low-risk patients who can tolerate the additive EPS risk for the benefit of improved clinical efficacy.
Data Source
Figure 1
Figure 2A~2B
AI summary
The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.